Quality of Life Is an Important Endpoint in Cancer Trials
Health-related quality of life (QOL) is becoming an increasingly important endpoint in cancer clinical trials.
Health-related quality of life (QOL) is becoming an increasingly important endpoint in cancer clinical trials, explained Giuseppe Lombardi, MD, PhD, a medical oncologist at the Veneto Institute of Oncology in Padua, Italy.
It is important that clinicians can offer patients not only the chance of improved survival, but also to live well in the meantime. This is especially true for patients with glioblastoma, who can have decreased neurologic or physical functioning. To ensure this, cancer treatment centers should assemble multidisciplinary teams that involve psychosocial supports, therapists, and more.